Table 1.

Baseline Demographic and Clinical Characteristics

Variable
Age at enrollment, years [mean (SD)]	50.1 (14.2)
Gender [n (%)]
Female	37 (39.8)
Male	56 (60.2)
Race or ethnic group [n (%)]
White	87 (93.5)
Black	3 (3.2)
Other	3 (3.2)
Ethnic group [n (%)]
Not Hispanic or Latino	90 (96.7)
Hispanic or Latino	2 (2.2)
Unknown	1 (1.1)
ANCA-associated vasculitis type [n (%)]
Granulomatosis with polyangiitis	90 (96.7)
Microscopic polyangiitis	3 (3.2)
Newly diagnosed at enrollment [n (%)]	41 (44.1)
Organ involvement at enrollment, by BVAS/WG [n (%)]
Ear, nose, and throat	70 (75.3)
Constitutional	65 (69.9)
Renal	60 (64.5)
Pulmonary	50 (53.7)
Mucous membranes and eyes	31 (33.3)
Cutaneous	20 (21.5)
Nervous system	19 (20.4)
Cardiovascular	1 (1.1)
Gastrointestinal	1 (1.1)
Other	7 (7.5)
BVAS/WG at enrollment [mean (SD)]	8.1 (3.1)
ESR at enrollment, mm/hr [mean (SD)]	36.0 (28.6)
CRP at enrollment, mg/dL [mean (SD)]	5.0 (12.4)
Creatinine at enrollment, mg/dL [mean (SD)]	1.0 (0.65)
Treatment group
Rituximab [n (%)]	50 (53.7)
Cyclophosphamide [n (%)]	43 (46.2)
Time to CR, months [median (IQR)]	5.9 (5.8 – 6.2)
Duration of follow-up after CR, months [median (IQR)]	35.6 (24.6 – 42.6)

SD, standard deviation; n, number; ANCA, antineutrophil cytoplasmic antibody; BVAS/WG, Birmingham Vasculitis Activity Score for Wegener Granulomatosis; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; CR, complete remission; IQR, interquartile range (25-75%)